Phase II trial of GM-CSF [granulocyte-macrophage colony-stimulating factors] in women with asymptomatic ovarian, primary peritoneal, or tubal carcinoma.
Phase of Trial: Phase II
Latest Information Update: 11 May 2017
At a glance
- Drugs Granulocyte-macrophage colony-stimulating factors
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 27 Apr 2012 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov
- 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Aug 2009 Bayer added as trial sponsor, lead trial centres and planned number of patients changed from 36 to 70 as reported by ClinicalTrials.gov.